Neovacs S.A. (EPA:ALNEV)
France · Delayed Price · Currency is EUR 0.7700
+0.0400 (5.48%)
Aug 3, 2026, 5:35 PM CET
Neovacs Revenue
In the year 2025, Neovacs had annual revenue of 161.78K EUR, down -44.46%. Neovacs had revenue of 71.05K in the half year ending December 31, 2025, a decrease of -83.52%.
Revenue
161.78K
Revenue Growth
-44.46%
P/S Ratio
0.58
Revenue / Employee
12.45K
Employees
16
Market Cap
116.12K
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 161.78K | -129.53K | -44.46% |
| Dec 31, 2024 | 291.31K | -242.11K | -45.39% |
| Dec 31, 2023 | 533.41K | 532.30K | 47,868.71% |
| Dec 31, 2022 | 1.11K | -21.43K | -95.07% |
| Dec 31, 2021 | 22.54K | -7.24K | -24.32% |
| Dec 31, 2020 | 29.78K | - | - |
| Dec 31, 2019 | 0 | - | - |
| Dec 31, 2018 | 0 | - | - |
| Dec 31, 2017 | 0 | - | - |
| Dec 31, 2016 | 15.43K | -132.46K | -89.57% |
| Dec 31, 2015 | 147.89K | 6.07K | 4.28% |
| Dec 31, 2014 | 141.82K | 111.95K | 374.77% |
| Dec 31, 2013 | 29.87K | - | - |
| Dec 31, 2012 | 0 | - | - |
| Dec 31, 2011 | - | - | - |
| Dec 31, 2010 | - | - | - |
| Dec 31, 2009 | - | - | - |
| Dec 31, 2008 | 54.37K | -72.49K | -57.14% |
| Dec 31, 2007 | 126.86K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Poxel | 7.66M |
| IntegraGen | 5.02M |
| Aelis Farma | 2.08M |
| Oncodesign Precision Medicine Société anonyme | 1.81M |
| Plant Advanced Technologies | 1.65M |
| Aton | 656.93K |
| GenSight Biologics | 652.00K |
| TME Pharma | 27.00K |